Finance

Beta
Lists
KYTX:NASDAQ
Kyverna Therapeutics Inc
$8.91
+1.48%
(+0.13) 1D
$9.30
+4.38% (+0.39)
After hours
Closed: Jun 30, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KYTX...
Open
$8.78
High
$9.25
Low
$8.65
Mkt. cap
541.69M
Avg. vol.
1.06M
Volume
93.00
52-wk high
$13.67
52-wk low
$2.52
EPS
-$3.28
Shares outstanding
60.80M
No. of employees
129
Open
$8.78
High
$9.25
Low
$8.65
Mkt. cap
541.69M
Avg. vol.
1.06M
Volume
93.00
52-wk high
$13.67
52-wk low
$2.52
EPS
-$3.28
Shares outstanding
60.80M
No. of employees
129
News stories
From sources across the web
About Kyverna Therapeutics Inc
CEO-
Employees129
Founded2018
HeadquartersEmeryville, California, United States
SectorBiotechnology
Websitekyvernatx.com
Analyst ratings
Based on 5 analysts giving stock ratings to KYTX in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for KYTX in the last 3 months.
Highest
Current $8.91
$33.00 (+270.37%)
Average
$30.00 (+236.70%)
Lowest
$25.00 (+180.58%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Ulz
Morgan Stanley
Buy
Maintained
$33.00
+270.4%
06/03/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
06/03/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$25.00
+180.6%
06/04/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
$29.00
+225.5%
05/13/2026
Derek Archila
Wells Fargo
Buy
Reiterated
$33.00
+270.4%
05/12/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
$30.00
+236.7%
03/30/2026
Last report
May 12, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.66 / -$0.73
+9.70%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
35.82M
30.46M
30.01M
30.07M
Cost of revenue
35.82M
30.46M
30.01M
30.07M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.59M
8.27M
9.27M
11.29M
Operating expense
8.59M
8.27M
9.27M
11.29M
Total operating expenses
44.41M
38.73M
39.28M
41.37M
Operating income
-44.41M
-38.73M
-39.28M
-41.37M
Other non operating income
-21.00K
-53.00K
17.00K
-21.00K
EBT including unusual items
-42.08M
-36.79M
-37.80M
-39.73M
EBT excluding unusual items
-42.08M
-36.79M
-37.80M
-39.73M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-42.08M
-36.79M
-37.80M
-39.73M
Net profit margin
-
-
-
-
Earnings per share
-0.97
-0.85
-0.80
-0.66
Interest and investment income
2.36M
2.00M
1.90M
2.33M
Interest expense
-14.00K
-7.00K
-444.00K
-667.00K
Net interest expenses
2.35M
1.99M
1.46M
1.66M
Depreciation and amortization charges
-
-
-
-
EBITDA
-44.37M
-37.84M
-38.91M
-41.02M
Gain or loss from assets sale
-
40.00K
20.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer